3 news items
Bio-Path Holdings Reports First Quarter 2024 Financial Results
BPTH
15 May 24
.Completed First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic
Bio-Path Holdings Provides 2024 Clinical and Operational Update
BPTH
2 Apr 24
Lymphoma and Chronic Lymphocytic Leukemia (CLL) – A Phase 1 clinical trial to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma
Bio-Path Holdings Reports Full Year 2023 Financial Results
BPTH
8 Mar 24
of BP1002 in refractory/relapsed lymphoma and refractory/relapsed Chronic Lymphocytic Leukemia (CLL). As we look to the months and year ahead, we expect
- Prev
- 1
- Next